Alexine Tranquada is passionate about improving patients’ lives and addressing health disparities.  She is an award winning pharmaceutical top talent with 25 years in and serving big pharma.  She has led teams at Schering-Plough and Merck in important global commercial functions including -market research, marketing, market access and business development- across the spectrum of therapeutic areas, including immunology, anti-infectives, cardiovascular, metabolics.  She evaluated numerous therapeutics for licensing or acquisition and led the market access assessment for the $11B acquisition of Promethius Bio by Merck in 2023.  

Alexine recently moved from New Jersey to Dallas and since then has taken a Healthcare Businesswomen’s Association board role as the President of Southwest Corporate Relations.  She is an advisor to several local biotech start-ups as well as involvement in non-profit organizations, including BioNTX, Gwen Lily Foundation and the Orchid Giving Circle.  She has also been a mentor to several start-ups through Health Wildcatters, Mass Challenge, and UTSW Dolphin Tank.  In addition to mentoring companies, she has also involved with women students in STEM through Young Women’s Preparatory Network and serves as a mentor for Healthcare Businesswomen’s Association.

In her spare time she likes to travel, spend time with her family (husband Warren, Ella, Calvin and Miles) and compete in triathalons.